Publications

Dr. Ostrin has authored more than 70 peer-reviewed publications. Below is a selection focused on lung cancer biomarkers and early detection. For the complete bibliography, see Google Scholar.

Full Publication List on Google Scholar →

Blood-Based Biomarker Panels & Screening

2026 Dennison JB, Gendarme S, Kettner NM, et al., Ostrin EJ, Hanash S. The LEAP Study: A Multicenter Biospecimen and Imaging Resource for Lung Cancer Screening.
Cancer Epidemiol Biomarkers Prev. 2026;35(1):39-48. PMID: 41191414
2025 Fahrmann JF, Irajizad E, Rudsari H, et al., Ostrin E, Hanash S. Validation of a blood test for multi-cancer risk stratification in a lung cancer screening cohort.
medRxiv. 2025. PMID: 41332848
2025 Gendarme S, Irajizad E, Long JP, et al., Ostrin EJ. Impact of Comorbidities on the Mortality Benefits of Lung Cancer Screening: A Post-Hoc Analysis of the PLCO and NLST Trials.
J Thorac Oncol. 2025;20(5):565-576. PMID: 39798695
2024 Irajizad E, Fahrmann JF, Toumazis I, et al., Ostrin EJ, Feng Z, Hanash S. Biomarker trajectory for earlier detection of lung cancer.
EBioMedicine. 2024;108:105377. PMID: 39353277
2024 Song L, Irajizad E, Rundle A, et al., Ostrin EJ, Fahrmann JF, Perera F, Hanash S. Validation of a Blood-Based Protein Biomarker Panel for a Risk Assessment of Lethal Lung Cancer in the Physicians' Health Study.
Cancers (Basel). 2024;16(11). PMID: 38893188
2023 Irajizad E, Fahrmann JF, Marsh T, et al., Ostrin EJ. Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on the Basis of the Prostate, Lung, Colorectal, and Ovarian Cohort.
Journal of Clinical Oncology. 2023;41(27):4360-4368. PMID: 37379494
2022 Fahrmann JF, Marsh T, Irajizad E, et al., Ostrin EJ, Spitz MR, Lam S, Shete S, Meza R, Tammemagi M, Feng Z, Hanash S. Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
Journal of Clinical Oncology. 2022;40(8):876-883. PMID: 34995129
2021 Ostrin EJ (co-first), Bantis LE (co-first), Wilson DO, et al., Yuan JM, Hanash S. Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules.
Journal of Thoracic Oncology. 2021;16(2):228-236. PMID: 33137463

Mechanisms of Lung Carcinogenesis

2023 León-Letelier RA, Abdel Sater AH, Chen Y, et al., Ostrin EJ (co-last), Fahrmann JF (co-last). Kynureninase Upregulation Is a Prominent Feature of NRF2-Activated Cancers and Is Associated with Tumor Immunosuppression and Poor Prognosis.
Cancers. 2023;15(3). PMID: 36765792
2022 Fahrmann JF, Tanaka I, Irajizad E, et al., Ostrin EJ, Hanash S, Vykoukal JV. Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma.
Cancers. 2022;14(10). PMID: 35626147
2016 Tripathi SC, Peters HC, Taguchi A, et al., Ostrin EJ. Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.
Proc Natl Acad Sci USA. 2016;113(11):E1555-E1564. PMID: 26929325
2017 Vykoukal JV, Sun N, Aguilar-Bonavides C, et al., Ostrin EJ, Hanash S. Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma.
Oncotarget. 2017;8(56):95466-95480. PMID: 29221141

Reviews & Perspectives

2025 Ostrin E. Fragments of a Story: Could Mitochondrial DNA Fragmentomics Upend Lung Cancer Early Diagnosis?
Am J Respir Crit Care Med. 2025. PMID: 41123928
2025 McGann KC, Khalil TA, Kammer MN, et al., Ostrin EJ, Maldonado F, Grogan EL. Biomarkers for the diagnosis of indeterminate pulmonary nodules.
Journal of Thoracic Disease. 2025;17(8):6265-6282. PMID: 40950900
2024 Moghaddam SJ, Savai R, Salehi-Rad R, et al., Ostrin EJ, et al. (ATS Research Statement). Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer.
Am J Respir Crit Care Med. 2024;210(5):548-571. PMID: 39115548
2023 Deboever N, Ostrin EJ, Antonoff MB. Liquid Biopsy as an Adjunct to Lung Screening Imaging.
Thorac Surg Clin. 2023;33(4):411-419. PMID: 37806743
2020 Ostrin EJ, Sidransky D, Spira A, Hanash S. Biomarkers for lung cancer screening and detection.
Cancer Epidemiol Biomarkers Prev. 2020;29(12):2411-2415. PMID: 33093160
2018 Hanash S, Ostrin EJ, Fahrmann JF. Blood based biomarkers beyond genomics for lung cancer screening.
Translational Lung Cancer Research. 2018;7(3):327-335. PMID: 30050770

This page highlights work most directly tied to lung cancer biomarkers. The full bibliography — including basic lung developmental biology, immunology, and earlier training-era publications — is available via Google Scholar.